PRF Technologies (PRFX) Income from Continuing Operations (2020 - 2024)
PRF Technologies' (PRFX) quarterly Income from Continuing Operations came in at 7600000.0 in Q2 2024, down 204.12% YoY from 7299154.5 in Q3 2023, and down 30.63% on a QoQ basis from 5818000.0 in Q1 2024.
PRF Technologies (PRFX) Income from Continuing Operations (2020 - 2024) Analysis & Trends
PRF Technologies (PRFX) has 5 years of Income from Continuing Operations data on file, last reported at 7600000.0 in Q2 2024.
- Quarterly Income from Continuing Operations fell 204.12% year-over-year to 7600000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was 7600000.0 (down 204.12% YoY) and the FY2025 annual result came in at 5022000.0, up 66.16% from the prior year.
- Income from Continuing Operations declined to 7600000.0 in Q2 2024, from 5818000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 132000.0 in Q1 2020 to a low of 10740000.0 in Q4 2023.
- A 5-year average of 3571611.11 and a median of 2294000.0 in 2021 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations slumped 1606.06% — and 2023, when it surged 31.46%.
- Tracing PRFX's Income from Continuing Operations over 5 years: stood at 4167000.0 in 2020, then plunged by 65.42% to 6893000.0 in 2021, then declined by 28.75% to 8875000.0 in 2022, then dropped by 21.01% to 10740000.0 in 2023, then climbed by 29.24% to 7600000.0 in 2024.
- The last three Income from Continuing Operations figures came in at 7600000.0 (Q2 2024), 5818000.0 (Q1 2024), and 10740000.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | PRF Technologies | 644,409.14 | -3.50 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -7.60 Mn |
| Mar 31, 2024 | -5.82 Mn |
| Dec 31, 2023 | -10.74 Mn |
| Sep 30, 2023 | -1.60 Mn |
| Jun 30, 2023 | -2.50 Mn |
| Mar 31, 2023 | -2.66 Mn |
| Dec 31, 2022 | -8.88 Mn |
| Sep 30, 2022 | -2.34 Mn |
| Jun 30, 2022 | -2.08 Mn |
| Mar 31, 2022 | -1.91 Mn |
| Dec 31, 2021 | -6.89 Mn |
| Sep 30, 2021 | -2.00 Mn |
| Jun 30, 2021 | -1.88 Mn |
| Mar 31, 2021 | -2.25 Mn |
| Dec 31, 2020 | -4.17 Mn |
| Sep 30, 2020 | -700,000.00 |
| Jun 30, 2020 | -148,000.00 |
| Mar 31, 2020 | -132,000.00 |